Aspira Women's Health Files 8-K
Ticker: AWHL · Form: 8-K · Filed: Sep 18, 2025 · CIK: 926617
Sentiment: neutral
Topics: material-definitive-agreement, equity-securities, filing
TL;DR
Aspira Women's Health filed an 8-K on 9/16/25 detailing material agreements and equity sales.
AI Summary
On September 16, 2025, Aspira Women's Health Inc. entered into a material definitive agreement. The company also reported on unregistered sales of equity securities and other events. This filing includes financial statements and exhibits.
Why It Matters
This 8-K filing indicates significant corporate actions and financial disclosures by Aspira Women's Health Inc., which could impact investors' understanding of the company's current status and future prospects.
Risk Assessment
Risk Level: medium — 8-K filings often contain material information that can lead to stock price volatility.
Key Players & Entities
- Aspira Women's Health Inc. (company) — Registrant
- September 16, 2025 (date) — Date of earliest event reported
- VERMILLION, INC. (company) — Former company name
- CIPHERGEN BIOSYSTEMS INC (company) — Former company name
- ABIOTIC SYSTEMS (company) — Former company name
FAQ
What type of material definitive agreement did Aspira Women's Health Inc. enter into?
The filing does not specify the exact nature of the material definitive agreement, only that one was entered into on September 16, 2025.
What is the significance of the 'Unregistered Sales of Equity Securities' item?
This indicates that the company has sold equity securities without registering them with the SEC, which may have implications for dilution and investor rights.
When was Aspira Women's Health Inc. incorporated?
The company was incorporated in Delaware.
What is the company's fiscal year end?
The company's fiscal year ends on December 31.
What were the previous names of Aspira Women's Health Inc.?
The company was formerly known as VERMILLION, INC., CIPHERGEN BIOSYSTEMS INC, and ABIOTIC SYSTEMS.
Filing Stats: 735 words · 3 min read · ~2 pages · Grade level 10.9 · Accepted 2025-09-18 09:00:51
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share AWHL OTC QB Market Indi
- $0.45 — 's Common Stock, at a purchase price of $0.45 per share of Common Stock and accompany
- $0.75 — y upon issuance at an exercise price of $0.75 per share and have a term of exercise e
- $2.95 m — he Private Placement were approximately $2.95 million, before deducting estimated offer
Filing Documents
- form8-k.htm (8-K) — 45KB
- ex4-1.htm (EX-4.1) — 105KB
- ex10-1.htm (EX-10.1) — 214KB
- ex99-1.htm (EX-99.1) — 18KB
- 0001493152-25-013987.txt ( ) — 623KB
- awhl-20250916.xsd (EX-101.SCH) — 3KB
- awhl-20250916_lab.xml (EX-101.LAB) — 33KB
- awhl-20250916_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Aspira Women's Health Inc. Date: September 18, 2025 By: /s/ Michael Buhle Michael Buhle, Chief Executive Officer -3-